STOCK TITAN

Adaptimmune Therapeutics plc - $ADAP STOCK NEWS

Welcome to our dedicated page for Adaptimmune Therapeutics plc news (Ticker: $ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adaptimmune Therapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adaptimmune Therapeutics plc's position in the market.

Rhea-AI Summary

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 2024 results, highlighting a cash runway through late 2025. Revenue fell to $5.7M from $47.6M YoY due to the termination of the Astellas collaboration. Net loss was $48.5M, compared to a $1.0M profit in Q1 2023. R&D expenses rose to $35.2M, driven by increased employee costs and lease properties from the TCR2 acquisition. G&A expenses decreased to $19.7M due to restructuring and lower corporate costs. The FDA is reviewing afami-cel for advanced synovial sarcoma with a PDUFA date of August 4, 2024. The company plans to launch afami-cel upon approval and lete-cel for synovial sarcoma and MRCLS in 2026, targeting peak U.S. sales of $400M. A $125M debt facility with Hercules Capital was secured.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
-
Rhea-AI Summary

Adaptimmune has secured a $125 million debt financing deal with Hercules Capital. The agreement includes an initial $25 million tranche available upon closing and an additional $25 million contingent on the approval of afami-cel. The remaining $75 million will be available subject to certain conditions. This financing aims to bolster the company's balance sheet as it prepares for the commercial launch of afami-cel later this year and lete-cel in 2026. Adaptimmune's CFO, Gavin Wood, expressed confidence in the potential impact of afami-cel on sarcoma treatment. A live webcast will provide further Q1 financial and business updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
none
-
Rhea-AI Summary

Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report Q1 2024 financial results and business updates on May 15, 2024. The company specializes in solid tumor cancer treatment using cell therapy. A live webcast will follow the announcement at 8:00 a.m. EDT (1:00 p.m. BST) on the same day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences earnings
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) terminates strategic collaboration with Genentech, remains focused on launching afami-cel with a PDUFA date of August 4th and developing its sarcoma franchise. Update on launch plans to be provided at the April 18th Investor Day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.08%
Tags
none
-
Rhea-AI Summary
Adaptimmune Therapeutics plc (ADAP) announces the publication of pivotal Phase 2 data with afami-cel in The Lancet, showcasing promising results in treating advanced synovial sarcoma and myxoid/round cell liposarcoma. The study demonstrates a 39% overall response rate in synovial sarcoma, indicating potential life extension and reduced chemotherapy dependence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Adaptimmune Therapeutics plc reported the U.S. FDA accepting BLA for afami-cel for advanced synovial sarcoma treatment with a priority review and a PDUFA date of August 4th, 2024. The company aims to launch afami-cel upon FDA approval with a sales projection of up to $400 million. The sarcoma franchise includes afami-cel and lete-cel, targeting synovial sarcoma and MRCLS patients. Financially, the company has a cash runway into early 2026 with over $300 million in cash. Clinical pipeline updates show promising results for ADP-A2M4CD8 in various solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.12%
Tags
Rhea-AI Summary
Adaptimmune reappoints Cintia Piccina as Chief Commercial Officer to lead the launch of afami-cel for advanced synovial sarcoma treatment. The company aims to leverage her expertise in cell therapy and commercialization as they prepare for the product's market entry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
management earnings
-
Rhea-AI Summary
Adaptimmune Therapeutics plc (ADAP) to report financial results and business updates for Q4 and full year 2023, with a live webcast scheduled on March 6, 2024. Investors can access the press release and webcast details on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
conferences
-
Rhea-AI Summary
Adaptimmune Therapeutics plc announced that the U.S. FDA has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. If approved, it will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in over a decade. The Prescription Drug User Fee Act (PDUFA) target action date is August 4, 2024. Clinical trials have shown an impressive response rate of ~39% among heavily pre-treated patients with advanced synovial sarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) announced plans for its emerging sarcoma franchise, projecting peak US sales of up to $400 million. The company aims to launch afami-cel in the US in 2024 and lete-cel in 2026. The pivotal trial for lete-cel met its primary endpoint for efficacy, and the company is funded into early 2026 with over $300 million, including existing balance sheet and projected payments from partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.33%
Tags
none
Adaptimmune Therapeutics plc

Nasdaq:ADAP

ADAP Rankings

ADAP Stock Data

268.34M
734.09M
0.2%
67.52%
1.3%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ABINGDON, OXFORDSHIRE

About ADAP

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.